Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21;10(15):3203.
doi: 10.3390/jcm10153203.

Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future

Jo Nijs  1   2   3 , Astrid Lahousse  1   4 , Eleni Kapreli  5 , Paraskevi Bilika  5 , İsmail Saraçoğlu  6 , Anneleen Malfliet  1   2   4 , Iris Coppieters  1   2 , Liesbet De Baets  1 , Laurence Leysen  1 , Eva Roose  1 , Jacqui Clark  1   7 , Lennard Voogt  1   8 , Eva Huysmans  1   2   4
Affiliations
Review

Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future

Jo Nijs et al. J Clin Med. .

Abstract

Recently, the International Association for the Study of Pain (IASP) released clinical criteria and a grading system for nociplastic pain affecting the musculoskeletal system. These criteria replaced the 2014 clinical criteria for predominant central sensitization (CS) pain and accounted for clinicians' need to identify (early) and correctly classify patients having chronic pain according to the pain phenotype. Still, clinicians and researchers can become confused by the multitude of terms and the variety of clinical criteria available. Therefore, this paper aims at (1) providing an overview of what preceded the IASP criteria for nociplastic pain ('the past'); (2) explaining the new IASP criteria for nociplastic pain in comparison with the 2014 clinical criteria for predominant CS pain ('the present'); and (3) highlighting key areas for future implementation and research work in this area ('the future'). It is explained that the 2021 IASP clinical criteria for nociplastic pain are in line with the 2014 clinical criteria for predominant CS pain but are more robust, comprehensive, better developed and hold more potential. Therefore, the 2021 IASP clinical criteria for nociplastic pain are important steps towards precision pain medicine, yet studies examining the clinimetric and psychometric properties of the criteria are urgently needed.

Keywords: central sensitization; neuropathic; nociceptive; nociplastic pain; precision medicine.

PubMed Disclaimer

Conflict of interest statement

J.N. and the Vrije Universiteit Brussel received lecturing/teaching fees from various professional associations and educational organizations, and J.N. authored a Dutch book on central sensitization. The remaining authors have nothing to disclose.

Figures

Figure 1
Figure 1
Clinical decision-making tree of the IASP clinical criteria for nociplastic pain.
See this image and copyright information in PMC

References

    1. Roberts N.L., Mountjoy-Venning W.C., Anjomshoa M., Banoub J.A.M., Yasin Y.J. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
    1. Cieza A., Causey K., Kamenov K., Hanson S.W., Chatterji S., Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;396:2006–2017. doi: 10.1016/S0140-6736(20)32340-0. - DOI - PMC - PubMed
    1. Vos T., Barber R.M., Bell B., Bertozzi-Villa A., Biryukov S., Bolliger I., Charlson F., Davis A., Degenhardt L., Dicker D., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-4. - DOI - PMC - PubMed
    1. Andersson G.B. Epidemiological features of chronic low-back pain. Lancet. 1999;354:581–585. doi: 10.1016/S0140-6736(99)01312-4. - DOI - PubMed
    1. Waddell G., Burton A.K. Occupational health guidelines for the management of low back pain at work: Evidence review. Occup. Med. 2001;51:124–135. doi: 10.1093/occmed/51.2.124. - DOI - PubMed

LinkOut - more resources